Agoracom Blog Home

Author Archive

$NAM.ca #Lithium Division Program Begins on Lithium One Project, Manitoba $LIX.ca $LI.ca $NLC.ca $SLL.ca

Posted by AGORACOM-JC at 8:48 AM on Tuesday, October 6th, 2020
  • NAM owns 100% of eight pegmatite hosted Lithium Projects in the Winnipeg River Pegmatite Field, located in SE Manitoba
  • The eight projects are strategically situated within the Winnipeg River Pegmatite Field, which hosts the world class Tanco Pegmatite that has been mined for Tantalum, Cesium and Spodumene (one of the primary Lithium bearing minerals) in varying capacities, since 1969
  • The program is being jointly funded by the Company and the new Manitoba Mineral Development Fund (MMDF) from the Manitoba Chamber of Commerce
  • The 2020 field work program will focus on follow up exploration of the company’s 2018 field reconnaissance efforts on the Lithium One Project
  • 2018 surface exploration completed on the Lithium One project yielded field samples grading up to 4.1% Li2O and 6.11% Rb2O
  • The Company has an exploration agreement in place with the Sagkeeng First Nation who the Company has engaged to work collaboratively with on completing the 2020 program at Lithium One
  • NAMs flagship project is the 100% owned River Valley Palladium Project, one of North America’s largest undeveloped primary Palladium Projects

October 6, 2020 – Rockport, Canada – New Age Metals Inc. (NAM) (TSXV:NAM ) ; ( OTC:NMTLF ) ; ( FSE:P7J) (“NAM” or the “Company”) is pleased to announce that the field work planned at the Company’s Lithium One Project in South east Manitoba, has begun. Harry Barr, Chairman & CEO stated; “With the help of a grant from the Manitoba Mineral Development Fund we are pleased to have our technical team and consultants in the field completing the fall program on our Lithium One Project.”

Lithium One Work Program

To complete this program, NAM plans to contract both Carey Galeschuk and Dave Owens, the Company’s consulting geologists in addition to the Twohearts Foundation, a Sagkeeng First Nations exploration service company. The fall 2020 program will include rock sampling, mapping and prospecting at the Company’s Lithium One project in the Greer Lake region. The objective of the program is to surface sample areas that have not been looked at to date at the project and further outline future drill targets.


Click Image To View Full Size

Figure 1 : NAM Project Location Map – Winnipeg River Pegmatite Field. Lithium One Project is highlighted.

Manitoba Mineral Development Fund

In June 2020, the Manitoba Government opened application to the MMDF which offered $20 million in funding to jump-start mineral and economic development initiatives in the north and throughout the province. The MMDF, delivered and administered by the Manitoba Chambers of Commerce, will support new economic development opportunities that capitalize on existing assets in the north and across Manitoba. Projects funded by MMDF will benefit Manitoba’s economy and local communities alike with a partnership-based approach to help grow and diversify the provincial economy together with Indigenous communities.

Manitoba COVID-19 Relief

The Company is taking advantage of relief measures put in place by the Manitoba government for mineral/mining claim holders in 2020. A one-year extension of time on all mining claims and mineral exploration licenses has been granted for claims and licences expiring prior to April 30, 2021. All of New Age Metals claims are eligible for this extension . Furthermore, the Manitoba Agriculture and Resource Development Department has extended double-assessment credits for exploration work completed in 2020. Both of these relief measures will assist the company in maintaining its land position in the Winnipeg River Pegmatite Field and the work completed at Lithium One will provide extended work credits for the Company on that project.

Lithium One Project

The project is geologically situated in the southern extension of the Bird River Greenstone Belt. The pegmatites are associated with the Greer Lake and Shatford Lake Pegmatite Group of the Cat Lake – Winnipeg River Pegmatite Field. The Winnipeg River Pegmatite Field hosts the World-Class Tanco Pegmatite which has been mined since 1969 at the Tanco Mine Site, in various capacities and for various commodities. This pegmatite field is hosted in the Archean age Bird River Greenstone Belt and into the surrounding granites.

The Silverleaf Pegmatite was historically mined in the late 1920’s for spodumene and probably represents one of the first spodumene operations in North America. The central, most economic, portion of the pegmatite is composed of lepidolite surrounded by an envelope of spodumene and quartz. The lepidolite zone outcrops as three large masses with lengths and maximum widths as follows: 23 m x 6 m (75 x 20 ft); 12 m x 4 m (40 x 12 ft); 5.5 m x 3 m (18 x 11 ft); it is also found in a westerly cut over a width of 2 m (6.5 ft). Spodumene is known to outcrop over a 334 m 2 (3600 sq ft). A quartz-spodumene crystal measuring 91 cm x 17 cm (3 ft x 7 inch) was reported near the core zone back in 1933.

Historic drilling of the Silverleaf Pegmatite from the 1950’s indicated a tabular pegmatite body dipping 30? S and extending 168 m (550 ft), while ranging in thickness from 5 to 11 m over a drilled length of 245 m.

The Company’s Phase One Exploration Program in 2018 , sampled several of the known lithium-bearing pegmatites. The purpose of the exploration program was to obtain modern-day assay analyses of the Pegmatites and to ground proof some of the historic Pegmatite locations. Numerous Pegmatites and Pegmatite swarms were not sampled in the 2018 program and will be explored during the 2020 fall program.


Click Image To View Full Size

Figure 2: Annie Pegmatite showing an outcrop with abundant SQUI (Spodumene Quartz Intergrowths) mineralization – The pen in the photo is 8 cm in length.

About NAM

New Age Metals is a junior mineral exploration and development company focused on the discovery, exploration and development of green metal projects in North America. The Company has two divisions; a Platinum Group Metals division and a Lithium/Rare Element division. The PGM division includes the 100% owned, multi-million-ounce, district scale River Valley Project, one of North America’s largest undeveloped Platinum Group Metals Projects, situated 100 km from Sudbury, Ontario. The Company has recently completed a Preliminary Economic Assessment on the project and is working towards Prefeasibility. In Alaska the Company owns 100% of the Genesis PGM-Cu-Ni Project in Alaska. The Lithium division is the largest mineral claim holder in the Winnipeg River Pegmatite Field, where the Company is exploring for hard rock lithium and various rare elements such as tantalum and rubidium. Our philosophy is to be a project generator with the objective of optioning our projects with major and junior mining companies through to production. The Company is actively seeking an option/ joint venture partner for its road-accessible Genesis PGM Cu-Ni project in Alaska and for our Lithium division in Manitoba.


Click Image To View Full Size

Figure 4: White spodumene blades in a matrix of lepidolite (Lithium Mica) from the Silverleaf showing.

New Age Metals is a junior resource company on the TSX Venture Exchange, trading symbol NAM, OTCQB: NMTLF; FSE: P7J with 138,854,511 shares issued to date. Investors are invited to visit the New Age Metals website at www.newagemetals.com where they can review the company and its corporate activities. Any questions or comments can be directed to [email protected] or Harry Barr at [email protected] or Cody Hunt at [email protected] or call 613 659 2773.

About the River Valley Palladium Project

The details of the updated Mineral Resource Estimate (MRE) and Preliminary Economic Assessment (PEA) were announced in the press release dated August 9, 2019 and are described on NAM’s website. The pit constrained Updated Mineral Resource Estimate formed the basis of the PEA . At a cut-off grade of 0.35 g/t PdEq, the Updated Mineral Resource Estimate contains 2.867 Moz PdEq in the Measured plus Indicated classifications and 1.059 Moz PdEq in the Inferred classification. The PEA is a preliminary report, but it demonstrates that there are potentially positive economics for a large-scale mining open pit operation, with 14 years of Palladium production. Refer to the NAM website (www.newagemetals.com) for details.

Opt-in List

If you have not done so already, we encourage you to sign up on our website ( www.newagemetals.com ) to receive our updated news.

Qualified Person

The contents contained herein that relate to Exploration Results or Mineral Resources is based on information compiled, reviewed or prepared by Carey Galeschuk, a consulting geoscientist for New Age Metals. Mr. Galeschuk is the Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the technical content of this news release with regard to technical aspects of the Lithium Division.

On behalf of the Board of Directors

” Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forw ard-looking statements.

Hollister Biosciences $HOLL.ca 100% Owned Subsidiary Venom Extracts Achieves Initial $30 Million Revenue Milestone $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:16 AM on Tuesday, October 6th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020
  • 100% owned subsidiary, Venom Extracts achieved the first of two revenue milestones in accordance with the terms of the definitive agreement
  • As a result, the Company will issue 19,740,036 common shares to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share

VANCOUVER, BC , Oct. 6, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (Frankfurt: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 230 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce that further to the news release dated March 30 th , 2020, its 100% owned subsidiary, Venom Extracts (” Venom “) has achieved the first of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company (the ” Transaction “).

On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020. As a result, the Company will issue 19,740,036 common shares (the ” Earn-Out Shares “) to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

“We are very pleased with the performance of the Arizona team in their ability to achieve this key milestone so expeditiously,” shared Carl Saling , CEO of Hollister .

None of the securities to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ” U.S. Securities Act “), or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Empower Clinics $CBDT.ca Acquires Medical Laboratory Capable of Processing 4,000 #COVID-19 RT-PCR Tests Per Day $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:02 AM on Tuesday, October 6th, 2020

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX, will advance Empower COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses, colleges and universities

  • Pursuant to the terms of a membership interest purchase agreement dated October 5, 2020, has completed the acquisition of Kai Medical Laboratory, LLC (“KAI“) from KTM5 Holdings, LLC, NULV11, LLC and Consistent Investment Group, LLC (together, the “Vendors“), through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for consideration having an aggregate value of US$1,971,857 (CAD$2,613,478), effective as of October 5, 2020 (the “Transaction“).

VANCOUVER BC / October 6, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) is pleased to announce that, pursuant to the terms of a membership interest purchase agreement dated October 5, 2020, has completed the acquisition of Kai Medical Laboratory, LLC (“KAI“) from KTM5 Holdings, LLC, NULV11, LLC and Consistent Investment Group, LLC (together, the “Vendors“), through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for consideration having an aggregate value of US$1,971,857 (CAD$2,613,478), effective as of October 5, 2020 (the “Transaction“).

COVID-19 RT-PCR TESTING IS THE GOLD STANDARD THAT ALLOWS EMPOWER TO ROLL OUT NATIONAL PHASE 4 TESTING PROGRAMS

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

“Adding Kai Medical Laboratory to the Empower Clinics family enables us to dramatically expand COVID-19 testing capability, for our get back to work & get back to school initiatives as part of our national rollout plans” said Steven McAuley, Empower’s Chairman & CEO. “Kai Medical has a newly built high-complexity lab offering a wide array of testing services, that we will leverage to serve the massive demand for national COVID testing in the U.S. Additionally, as flu season arrives and a potential second-wave of COVID takes hold, the technical infrastructure of Kai Medical allows Empower to capture testing demand and bring new technical testing products to market.”

COVID-19 TESTING PROGRAMS FOR EMPLOYERS AND DIRECT TO CONSUMER ALREADY UNDERWAY AT KAI LABORATORY

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

Finally, beyond its COVID-19 capabilities, Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals and pharmacists.

KAI MEDICAL LABORATORY TEAM LEAD BY YOSHI TYLER

The driving force behind Kai Medical Laboratory’s remarkable growth and success is Yoshi Tyler. Yoshi has a passion for being an entrepreneur, and over time, she found her true calling in healthcare. Driven by this interest, she pursued her career in the healthcare industry for more than two decades. She held leadership positions at a Fortune 500 pharmaceutical company for over thirteen years. These leadership experiences provided her with in-depth knowledge and industry insights that helped her to lead Kai Medical Laboratory towards growth.

The Kai Medical Laboratory team includes key roles including Principal Scientist, Director of Operations, Molecular Scientist, Quality Assurance, Lab Director and other critical roles.

“Kai Medical Laboratory is inspired by science and built on integrity and joining Empower allows our highly skilled personnel and state-of-the-art instrumentation to expand from a local community level to a national level” says Yoshi Tyler, Founder of Kai Medical. “Our mission is to change healthcare through science & innovative quality care, and with Empower providing an expansion of resources, Kai Medical Laboratory will be in a position to help the national need for expanded COVID-19 testing as the second wave commences.”

ADDITIONAL TERMS OF THE ACQUISITION

In connection with the closing of the Transaction (the “Closing“), Empower; (i) assumes certain short term and long term liabilities comprised of the SBA Loan of (US$1,139,577), the EIDL Loan of (US$150,000), the PPP Loan of (US$86,379), revolving debt of (US$89,478), (ii), accounts payable of (US$192,460), (iii) other short term and long term liabilities of (US$313,963), in total equal to the amount of US$1,971,857 (CAD$2,613,478), (the “Assumed Indebtedness“); the issuance of options to purchase common shares of Buyer Parent at an exercise price of CDN$0.05 per share, subject to the terms and conditions of each of the Option Agreements, in an amount equal to 400,000 share options to Yoshi Tyler, as the principal of KTM5, and 100,000 share options to Michael Haines, as the principal of NULV11 (the “Options“); and the issuance of a warrant certificate to Continuous Investment Group, LLC to purchase 500,000 common shares of Buyer Parent at a purchase price of CDN$0.05 per share, subject to the terms and conditions of the Warrant Certificate (the “Warrants“).

Market Leading Technology Kai Medical Laboratory utilizes state-of-the-art instrumentation, preeminent testing methodologies, and laboratory services enabling high-complexity accredited laboratory testing solutions, providing some of the following key instrument testing capabilities:

  • Thermo Fisher – QuantStudio 12K Flex
    • COVID-19 testing
    • Cannabis Testing
    • Clinical Genomics
  • Roche Cobas 6000
    • COVID-19 Antibody testing
    • Clinical Chemistry/Endocrinology
  • AB SCIEX 6500+ – Liquid Chromatography Mass Spectrometry
    • Clinical Chemistry/Endocrinology
    • Agriculture/Cannabis testing
  • AB SCIEX 4500 – Liquid Chromatography Mass Spectrometry
    • Urine Toxicology
    • Cannabis testing
  • SYSMEX XN-550
    • Hematology

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

(COLA) is the premier clinical laboratory accreditation, education and consultation organization. An independent accreditor whose practical, educational standards have a positive and immediate impact on patient care. http://www.cola.org

ABOUT EMPOWER

Empower is an integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT Kai Medical Laboratory

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: EMPOWER CLINICS INC.

FansUnite Entertainment $FANS.ca Enters Partnership with Global Gaming Leader Pinnacle Solutions $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 6:52 AM on Tuesday, October 6th, 2020
  • Announced its partnership with Pinnacle to incorporate Pinnacle’s new esports data and odds feed into its Chameleon Gaming Platform
  • The partnership is part of its strategic plan to collaborate with the best data providers for its esports betting offering.
  • Through Pinnacle’s partnership with GRID Esports, they gain direct access to GRID’s contracts with esports leagues and tournaments, making it the best data source for many major esports events.
  • In partnering with Pinnacle, FansUnite can now offer the best odds on esports bets for its Chameleon Gaming Platform partners, giving it a competitive advantage over other turnkey B2B esports betting products.

Vancouver, British Columbia–(October 6, 2020) – FansUnite Entertainment Inc. (CSE: FANS) (OTC: FUNFF) (“FansUnite” or the “Company”), a technology company providing leading online gaming solutions, is pleased to announce its latest partnership with Pinnacle Solutions (“Pinnacle”), a global leader in online sports betting.

FansUnite is excited to announce its partnership with Pinnacle to incorporate Pinnacle’s new esports data and odds feed into its Chameleon Gaming Platform. The partnership is part of its strategic plan to collaborate with the best data providers for its esports betting offering. Through Pinnacle’s partnership with GRID Esports, they gain direct access to GRID’s contracts with esports leagues and tournaments, making it the best data source for many major esports events. In partnering with Pinnacle, FansUnite can now offer the best odds on esports bets for its Chameleon Gaming Platform partners, giving it a competitive advantage over other turnkey B2B esports betting products.

“We aim to partner with the leading companies in the industry to provide the best product and options to our customers using the Chameleon Platform. With Pinnacle’s addition and their relationship with GRID Esports, we continue to add the best esports betting data available with the most markets and the best odds. It’s exciting to be the first to offer Pinnacle Solution’ service, and we are honoured they chose to work with us,” stated FansUnite CEO Scott Burton.

“The next step is to effectively market the Chameleon Gaming Platform to sportsbooks,” continued Scott Burton. “We want to ramp up our B2B segment and get a guaranteed licensing fee when sportsbooks use our services. In addition, we generate additional income as our partners grow as we share in a percentage of the net gaming revenue giving us unlimited upside revenue potential. Partnering with Pinnacle will help take our B2B esports solution to a new level.”

Pinnacle’s CEO Paris Smith added, “We are really excited to announce this partnership with FansUnite. Pinnacle Solution is going from strength to strength and it’s great to see our product getting out there and enhancing the betting experience for customers around the world. We are always focused on getting the most value out of our partnerships for us and our partners. Our deal with FansUnite will certainly add to our experience as a supplier and we are really looking forward to working closely with their team and helping them achieve their goals.”

“Our B2B strategy is one that is built on laying solid foundations. Our continued growth, which includes deals like this, is a clear sign that we are working hard to build on our already impressive offering and keep leading the way for others to follow. Whether it’s the odds, the risk management, the data, we have the complete package as well as a best-in-class service to match.”

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

About Pinnacle Solution

Pinnacle Solution offers a comprehensive B2B sportsbook service built on the foundation of unrivalled risk management expertise and the unique ability to leverage Pinnacle’s 20+ years of industry experience as an operator.

In addition to its wide-ranging traditional sports offering, Pinnacle Solution is also renowned for being the leading supplier in esports betting. Winning multiple awards has positioned Pinnacle Solution as the gold standard in B2B esports betting, proven to help clients take their product to the next level.

For further information, please contact:

Prit Singh Investor Relations at FansUnite
[email protected]
(905) 510-7636

Scott Burton Chief Executive Officer of FansUnite
[email protected]

Darius Eghdami President of FansUnite
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events such as: the leveraging of GameCo’s US license infrastructure; GameCo becoming an official reseller of the platform; the Company’s entrance into the US market and the Company’s strategy with respect thereto; the importance of the US market to the Company; impacts of the GameCo/Askott partnership on the Company’s success; the Company’s ability to become a leading technology platform and a leader in the global I-gaming market, and to serve the gaming market; the potential growth of the Company and the gaming market; the increased number of betting options; the ability of the Company to scale its B2B arm and maintain its B2C platforms; the Company’s unique portfolio of assets; and discussion of future plans, projections, objectives, estimates and forecasts and the timing related thereto. Forward-looking statements are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Additional information regarding the risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

PyroGenesis $PYR.ca Announces Receipt of $4.8MM Down Payment under US Navy Contract $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:46 PM on Monday, October 5th, 2020
  • Received the first payment of approx. $4.8MM under the previously announced $11.5MM contract
  • The Contract is to provide two of PyroGenesis’ waste destruction systems, one for each ship of the US Navy’s two-ship build
  • Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81)

MONTREAL, Oct. 05, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products,  is pleased to announce that, further to its press release dated September 4th, 2020, it has received the first payment (“Down Payment”) of approx. $4.8MM under the previously announced $11.5MM contract (the “Contract”). The Contract is to provide two of PyroGenesis’ waste destruction systems (the “Systems”), one for each ship of the US Navy’s two-ship build.

The Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).

Separately, the Company expects to receive an additional $2.65MM from Drosrite International over the next few weeks.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com .

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

KWESST $KWE.ca Electronic Decoy Patent Receives Notice of Allowance from U.S. Patent Office $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 3:28 PM on Monday, October 5th, 2020
  • Announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the Company’s patent application covering its PhantomTM electronic battlefield decoy
  • Notice of Allowance from the USPTO covers fifteen patent claims for a programmable multi-waveform radio frequency generator capable of broadcasting and emulating all relevant military waveforms to create electronic battlefield decoys that deceive adversaries regarding the location of NATO friendly forces

Ottawa, Ontario–(October 5, 2020) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for the Company’s patent application covering its PhantomTM electronic battlefield decoy.

“This marks an important addition to KWESST’s technology portfolio,” said Jeff MacLeod, President and CEO, who added that, “The allowed claims cover both the miniaturized device itself and methods of deploying it, which we believe constitute significant protection of the invention.”

KWESST’s PhantomTM system addresses the latest requirements for miniaturized electronic decoys that can be easily deployed by soldiers or drones in contested areas of operation to prevent adversaries from accurately locating NATO forces. “Owning the patent that protects both the technology and the method of deployment gives KWESST a distinct advantage in a vast emerging market of next-generation electronic countermeasures,” said the Company.

The Notice of Allowance from the USPTO covers fifteen patent claims for a programmable multi-waveform radio frequency generator capable of broadcasting and emulating all relevant military waveforms to create electronic battlefield decoys that deceive adversaries regarding the location of NATO friendly forces.

The Company added that it is filing additional claims by way of a “Continuance” to expand the scope of its patent even further.

About KWESST

KWESST develops and commercializes high-value ultra-miniaturized technology applications that make a critical difference to the safety and operational effectiveness of personnel in the defence and security industries. The company’s current portfolio of unique proprietary offerings include: its signature TASCSTM (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons; the autonomous Grey GhostTM soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact; a Ground Laser Defence system to counter the emerging threat of weaponized lasers against personnel; and, the PhantomTM electronic battlefield decoy system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations to deceive and confuse adversaries. All systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems including Frontline, Edge, Killswitch and ATAK (Android Tactical Assault Kit) among others. KWESST also has developmental “smart ordnance” projects including its “Shot Counter” system, which records the number and type of rounds fired, for optimized firearms maintenance and performance. The Company is headquartered in Ottawa, Canada, with representative offices in Washington, DC, London, UK and Abu Dhabi, UAE. KWESST trades on the TSX Venture Exchange under the symbol KWE.

Contact: Jason Frame, Investor Relations. Email: [email protected]

Datametrex $DM.ca #AI Pandemic Management System Charting Hotspot Signs Of #COVID19 Outbreaks

Posted by AGORACOM-JC at 12:02 PM on Monday, October 5th, 2020
Webinar logo
  • Announced the development of an advanced statistical model to assess the current state of the pandemic and to monitor COVID-19 hotspots using Artificial Intelligence and Machine Learning
  • As the COVID-19 pandemic continues to spread around the globe, the Company is further developing its Nexalogy AI to build automated tracking systems that will mine vast amounts of data using NexaIntelligence, from social media and traditional news, for signs of new COVID-19 outbreaks being discussed in real-time
  • According to a 2018 study by the McKinsey Global Institute, entitled: Notes from the AI frontier: Applications and value of deep learning, these capabilities are estimated to have the potential to create between approximately $9.5 trillion and $15.4 trillion in annual global economic value

Toronto, Ontario–(October 5, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce the development of an advanced statistical model to assess the current state of the pandemic and to monitor COVID-19 hotspots using Artificial Intelligence (“AI”) and Machine Learning (“ML”).

Prior to the COVID-19 pandemic’s stranglehold on the world, leaders increasingly embraced advanced analytics and AI, for good reason. According to a 2018 study by the McKinsey Global Institute, entitled: Notes from the AI frontier: Applications and value of deep learning, these capabilities are estimated to have the potential to create between approximately $9.5 trillion and $15.4 trillion in annual global economic value.[1]

As the COVID-19 pandemic continues to spread around the globe, the Company is further developing its Nexalogy AI to build automated tracking systems that will mine vast amounts of data using NexaIntelligence, from social media and traditional news, for signs of new COVID-19 outbreaks being discussed in real-time.

Secondly, the Company is developing an early alarm mapping system to keep watch for the pandemic using an advanced ML statistical model to monitor COVID-19 on the Lexical Map. This is developed using automatic text analysis that identifies with coloured clusters the sub-themes to understand COVID-19 noise versus signal quickly and certainly underscores the potential of AI and ML.

Predicting positive results based on scientific mapping brings new developments to treatment in which clusters are systematically screened using computer algorithms for tracking and tracing for viral testing protocols leading to any subsequent quarantining and healthcare that may well be required.

This new system will collect and analyze COVID-19 data from Twitter, Facebook, Tumblr, blogs, web forums, online news sites, Google Alerts and RSS feeds.

“Our AI pandemic management and analytics platform supports the modelling and monitoring of COVID-19. By leveraging smartphones and other digital technology, we use our analytics to produce metrics that help governments and communities evaluate trends to enable strategic and efficient deployment of resources,” said Marshall Gunter, CEO of the Company.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.

Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.

Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

EVENT: Avicanna $AVCN.ca $AVCNF to Present at Live Growth Opportunities Investor Conference October 8th $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 10:44 AM on Monday, October 5th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Avicanna Inc. to Present at Live Growth Opportunities Investor Conference October 8th

REGISTER NOW AT: https://bit.ly/3lcIUNp 

Avicanna Presentation time: 10:30am

Blockchain Foundry $BCFN.ca Announces Blockchain Development Agreement with GDPR Compliance Solution Provider

Posted by AGORACOM-JC at 10:21 AM on Monday, October 5th, 2020
  • Entered into a blockchain development agreement with a client in the General Data Protection Regulation compliance space
  • The initial phase of the Agreement is valued at approximately $50,000 and will last for approximately four weeks

TORONTO, Oct. 05, 2020 — Blockchain Foundry Inc. (“BCF” or the “Company”) (CSE:BCFN), a leading North American blockchain development firm, has entered into a blockchain development agreement (the “Agreement”) with a client (the “Client”) in the General Data Protection Regulation (“GDPR”) compliance space. The initial phase of the Agreement is valued at approximately $50,000 and will last for approximately four weeks.

GDPR is a regulation in EU law concerning data protection and privacy. The market for GDPR compliance services in Europe is estimated to be worth approximately US$1.2 billion by 2023 1 .

Pursuant to the Agreement, BCF will work with the Client to complete the MVP of its GDPR compliance solution. The Client expects to undertake more product development beyond the MVP phase and BCF will have the opportunity to establish itself as the preferred vendor for future development initiatives.

About Blockchain Foundry Inc.

Blockchain Foundry develops and commercializes blockchain-based business solutions and provides consulting services to corporate clients seeking to incorporate blockchain technology into their businesses.

Blockchain Foundry Contact Information:

Chris Marsh
President
[email protected]
(647) 330-4572

Forward-Looking Information

Certain portions of this press release contain “forward-looking information” within the meaning of applicable Canadian securities legislation, which is also referred to as “forward-looking statements”, which may not be based on historical fact. Wherever possible, words such as “will,” “plans,” “expects,” “targets,” “continues,” “estimates,” “scheduled,” “anticipates,” “believes,” “intends,” “may,” “could,” “would” or might, and the negative of such expressions or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved, have been used to identify forward-looking information.

Forward-looking statements should not be read as guarantees of future events, future performance or results, and will not necessarily be accurate indicators of the times at, or by which, such events, performance or results will be achieved, if achieved at all. Readers should not place undue reliance on such forward-looking statements, as they reflect management’s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BCF are inherently subject to significant business, economic, regulatory, competitive, political and social uncertainties, and contingencies. Many factors could cause BCF’s actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements.

MEDIA: How Richard Carleton Is Leading The Cannabis Revolution At The #CSE – #Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 9:37 AM on Monday, October 5th, 2020

InnoCan Pharma (INNO:CSE) Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids. InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. Learn more.

Innocan-Blog

How Richard Carleton Is Leading The Cannabis Revolution At The CSE

Cannabis has emerged as a viable commodity for international trade, and the Canadian Stock Exchange is leading the charge.

  • A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations
  • InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes
  • This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

The growing cannabis market

As the cannabis industry continues to advance, more and more companies are moving to get their stocks listed on Canada Securities Exchange. Cannabis is no longer just a plant. The debate on its legality, decriminalization, health benefits, among others, are now the main focus of attention. Cannabis has emerged as a viable commodity for international trade, and raw material for consumption, with several companies listed on the stock market and shareholders who speculate on its rise or fall according to news of its legalization in more corners.

A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations. InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes. This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

Although the debate will always be present, more and more countries have chosen to decriminalize and even promote the use of cannabis, especially for medicinal purposes. The likes of Germany, Argentina, Italy, Canada, etc already allow the use of CBD derivatives to treat health problems, always under medical prescription, but often even facilitating their access to patients.

Cannabis for recreational activities is now an emerging discourse, and borders that seemed immovable a while ago have been crossed. Canada passed a regulation in 2018 that made it one of the few countries that fully allowed recreational consumption and the first of the G-8.

It thus joined Uruguay, a country that has always had a fairly permissive position. And the Netherlands, which despite the fame of its cannabis sale in coffee shops, has not changed its regulation in recent years (The Netherlands does not allow cultivation for self-consumption). As well as Mexico, who in a wide debate in recent years, have legalized marijuana for medical use. In the United States, almost 30 of its states have opened the door to medicinal consumption, and about 10 of them, including California, to recreational use.

The growth of the marijuana-related market has exploded in recent years and according to GlobeNewswire, “The global legal marijuana market size is expected to reach USD 73.6 billion by 2027.” This includes medicinal, recreational, and derivatives.

Furthermore, “It is anticipated to expand at a CAGR of 18.1% during the forecast period. The increasing legalization of cannabis for medical as well as adult-use is expected to promote growth. Based on type, the medical segment held the leading revenue share of 71% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease, and Alzheimer’s disease among other neurological conditions. Moreover, an increasing need for pain management therapies along with the growing disease burden of chronic pain among elders is expected to boost the product demand.”

In this context, in recent years numerous companies, especially in the pharmaceutical industry, have begun to fully immerse themselves in this buoyant market with the expectation that over time it will become increasingly legal in more countries. Most of these companies are Canadian, and they have emerged in the glow of the country’s decriminalization momentum.

Some are dedicated to distribution for recreational consumption, those that lean more to the medical side, and those that are specializing in derivatives. Several things unite them: they are all Canadian for their reference in legalization, they are all growing, and a lot of them have successfully been listed on the stock market.

Canadian Securities Exchange (CSE)

Without a doubt, the Canadian Securities Exchange (CSE) has played a vital role in strengthening the marijuana-related market in Canada. Led by a visionary CEO, Richard Carleton, it has emerged as one of the pillars of cannabis investment in the country. Exchange operators have critically guided affairs, bringing about the availability of a variety of investment options for cannabis investors.

The CSE is Canada’s fastest-growing stock exchange. With more than 600 listings and a cumulative market capitalization of approximately C$23 billion, the Exchange continues to attract entrepreneurial companies that are looking for the most efficient path to the North American capital markets. With the help of the Canada Securities Exchange, Canadian companies can choose to test the waters outside Canada, particularly in the United States, as long as they can allay the fears of shareholders. Presently, cannabis is illegal on a federal level in the USA, however, it is legal for medical and recreational purposes in a good number of states.

The Canadian Securities Exchange (CSE) is the go-to platform for cannabis companies who are still developing. It offers much-needed exposure for the growth of these emerging companies, while also giving established organizations, such as multi-state operators in the US, a chance to gain a competitive advantage in the global market.

According to Richard Carleton, “It is always gratifying to see companies capitalizing on opportunities in the public market to pursue their vision for growth. The CSE has a mandate to facilitate entrepreneurial activity such as this.”

Looking at the medical aspect, he further believes that large and small companies have complementary roles in the pharmaceutical industry. Start-up companies play an important role in conducting early research and development in identifying new drug therapies. History shows that a lot of value creation happens in this space before the drugs are taken through clinical trials and ultimately brought to the market by the pharma giants and are prescribed to patients worldwide. In addition, regardless of their size, pharma companies need to have exceptional technical and logistical talent to develop a drug and move it through regulated trials.

Presently, there is a tremendous amount of effort in the pursuit of therapies and vaccines for COVID-19. This recent activity is a good reminder of how powerful the public markets are at organizing capital to solve real-world issues. You can be sure that whatever health challenge society is presented with next, the market will be here to find solutions.

https://seekingalpha.com/instablog/52407514-dennz54/5504073-how-richard-carleton-is-leading-cannabis-revolution-cse